Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
Doctors are testing a new treatment for a type of cancer called multiple myeloma. The treatment is a drug called 211At-OKT10-B10. It is made up of a special antibody and a radioactive substance that kills cancer cells. The doctors will also use a chemotherapy drug called melphalan. Together, these treatments might be able to kill more cancer cells. They will give the treatment to patients before a stem cell transplant. The doctors will study how well the treatment works and if it has any side effects.
Doctors are testing a new treatment for a type of cancer called multiple myeloma. The treatment is a drug called 211At-OKT10-B10. It is made up of a special antibody and a radioactive substance that kills cancer cells. The doctors will also use a chemotherapy drug called melphalan. Together, these treatments might be able to kill more cancer cells. They will give the treatment to patients before a stem cell transplant. The doctors will study how well the treatment works and if it has any side effects.
*Third Opinion AI Generated Synopsis
Trial Summary
This phase I trial studies the side effects and best dose of 211At-OKT10-B10 when given together with melphalan before a stem cell transplantation in treating patients with multiple myeloma. The radioimmunotherapy drug 211At-OKT10-B10 is a monoclonal antibody, called OKT10-B10, linked to a radioactive substance called 211At. OKT10-B10 attaches to CD38 positive cancer cells in a targeted way and delivers 211At to kill them. Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving 211At-OKT10-B10 with melphalan before a stem cell transplant may kill more cancer cells.
This phase I trial studies the side effects and best dose of 211At-OKT10-B10 when given together with melphalan before a stem cell transplantation in treating patients with multiple myeloma. The radioimmunotherapy drug 211At-OKT10-B10 is a monoclonal antibody, called OKT10-B10, linked to a radioactive substance called 211At. OKT10-B10 attaches to CD38 positive cancer cells in a targeted way and delivers 211At to kill them. Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving 211At-OKT10-B10 with melphalan before a stem cell transplant may kill more cancer cells.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: